“Our transformation into ROIS reflects both our present situation and our future. We are proud of our legacy and excited about what lies ahead: growing, investing, and expanding our capacity to meet the needs of our partners worldwide,”
Fri, 03/10/2025 - 10:43
3 min“Our transformation into ROIS reflects both our present situation and our future. We are proud of our legacy and excited about what lies ahead: growing, investing, and expanding our capacity to meet the needs of our partners worldwide,”
rgb_variation_1-full_colour.png
We are pleased to introduce ROIS, a new brand identity that continues the transformation of our third-party manufacturing activity (CDMO). This evolution strengthens our leadership and drives us to keep creating value for both our business and our clients.
ROIS represents the natural evolution of ROVI Pharma Industrial Services. It embodies a new image that reflects a path of sustained growth, consolidating our position as a global CDMO while clearly projecting our future vision: to be a company that continuously expands its capabilities while remaining a trusted partner to the world’s leading pharmaceutical companies.
The launch of this new brand identity coincides with the announcement of an agreement to acquire a state-of-the-art facility for the manufacturing and packaging of injectable medicines in Phoenix, Arizona (United States). This milestone marks a significant step forward for the company, enabling direct manufacturing for pharmaceutical and biotechnology partners in one of the world’s most important markets, the United States.
“Our transformation into ROIS reflects both our present situation and our future. We are proud of our legacy and excited about what lies ahead: growing, investing, and expanding our capacity to meet the needs of our partners worldwide,” explained Javier López-Belmonte, Vice Chairman of the Board & Chief Financial Officer at ROVI.
A new brand for a new era
The ROIS brand signals the next stage in the company’s evolution. ROVI Pharma Industrial Services has built a reputation as a trusted partner for injectable development and manufacturing, and the rebrand reflects its continued investment in capacity, technology and service.
“Our transformation into ROIS reflects where we are today and where we are headed,” said López-Belmonte. “We are proud of our legacy and excited about our future — growing, investing, and expanding capacity to meet our partners’ needs worldwide.”
Significant US manufacturing capability
The Phoenix facility comprises approximately 34,000 m² on an ~80,000 m² site and has benefited from ~$100m CAPEX since 2021. The site includes a cytotoxic/high-potent (OEB5) area and holds regulatory approvals from FDA, EMA and Japanese authorities. ROIS plans to install an Optima pre-filled syringe (PFS) isolator line in 2027, projected to add ~65–70 million PFS capacity annually once operational. The US facility is equipped for commercial-scale sterile fill-finish and packaging across vials, PFS and cartridges.
With this expansion, ROIS will:
The rebrand and US expansion underline ROIS’s vision to be a partner of choice for injectable medicines worldwide, underpinned by continued investment in people, technology and infrastructure.
“This acquisition is a strategic step in building ROIS as a global CDMO for high-value injectables,” added López-Belmonte. “The Phoenix site adds significant sterile fill-finish and high-potent capability, enabling us to better serve partners on US soil while continuing to invest across our network.”
For more information, visit www.roiscdmo.com.